Cognition Therapeutics, Inc. Banner Image

Cognition Therapeutics, Inc.

  • Ticker CGTX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Cognition Therapeutics, Inc. Logo Image
  • 11-50 Employees
  • Based in Purchase, New York
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. They are currently investigating their lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dryMore age-related macular degeneration (dry AMD). They believe CT1812 and their pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these diseases. They believe that targeting the σ-2 receptor with CT1812 represents a mechanism functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases.
Cognition Therapeutics, Inc.

Most Recent Annual Report

Cognition Therapeutics, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Cognition Therapeutics, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!